<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">808</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2025-12-4-139-148</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of disulfide isomerases in post-translational modification of NaPi2b (<italic>SLC34A2</italic>) in ovarian carcinoma cells</article-title><trans-title-group xml:lang="ru"><trans-title>Роль дисульфид-изомераз в посттрансляционной модификации NaPi2b (<italic>SLC34A2</italic>) в клетках карциномы яичника</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0082-6833</contrib-id><name-alternatives><name xml:lang="en"><surname>Vlasenkova</surname><given-names>R. A.</given-names></name><name xml:lang="ru"><surname>Власенкова</surname><given-names>Р. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>r.mukhamadeeva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-3161-2210</contrib-id><name-alternatives><name xml:lang="en"><surname>Rybachuk</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Рыбачук</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kiyamova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2547-2843</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiyamova</surname><given-names>R. G.</given-names></name><name xml:lang="ru"><surname>Киямова</surname><given-names>Р. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kiyamova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University</institution></aff><aff><institution xml:lang="ru">Институт фундаментальной медицины и биологии ФГАОУ ВО «Казанский (Приволжский) федеральный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2025</year></pub-date><volume>12</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>139</fpage><lpage>148</lpage><history><date date-type="received" iso-8601-date="2025-08-29"><day>29</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Vlasenkova R.A., Rybachuk I.A., Kiyamova R.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Власенкова Р.А., Рыбачук И.А., Киямова Р.Г.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Vlasenkova R.A., Rybachuk I.A., Kiyamova R.G.</copyright-holder><copyright-holder xml:lang="ru">Власенкова Р.А., Рыбачук И.А., Киямова Р.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/808">https://umo.abvpress.ru/jour/article/view/808</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>.<bold> </bold>Ovarian cancer is characterized by high recurrence rate and chemoresistance, therefore identification of new markers for prognosis of disease progression and understanding of fundamental processes during oncogenic transformation remain important problems. Membrane phosphate transporter NaPi2b coded by the SLC34A2 gene is highly expressed in this pathology and serves as a target for antitumor therapy with monoclonal antibodies against МХ35 epitope. We have shown that availability of MX35 epitope depends on the conformation of its large extracellular domain determined by disulfide bonds (S-S-bonds) between cysteines in positions 303, 322, 328 and 350. Protein disulfide isomerase (PDI) family proteins regulate formation and rearrangement of S-S-bonds.</p> <p><bold>Aim</bold>. Network analysis of interactions between SLC34A2 and PDI family genes, as well as their products in samples of normal and tumor ovarian tissues for identification of key regulators of posttranslational modification of NaPi2b in tumor tissues.</p> <p><bold>Materials and methods</bold>. Data on interactions of the selected genes were obtained from the Gene Ontology, String, KEGG, Reactome, WikiPathways, InterPro and Pfam databases. Based on the information on co-expression and protein-protein interactions, networks of interactions between 16 genes of the PDI family and SLC34A2 gene and their products were constructed and analyzed.</p> <p><bold>Results</bold>. Topological analysis revealed absence of structural similarity of the networks (cophenetic correlation coefficient = 0.082), and in tumors specific key genes were identified: CASQ1, CASQ2, ERP29, PDIA5, TMX4 and SLC34A2. The main result is conflation of ERP29 and SLC34A2 genes into common functional module with reverse co-expression (Spearman’s rank correlation coefficient = –0.42; p &lt;0.05) only in the tumor cell interaction network. This indicates potential role of ERP29 protein in pathological rearrangement of disulfide bonds of the NaPi2b extracellular domain and maintenance of availability of tumor-associated MX35 epitope in transformed cells.</p> <p><bold>Conclusion</bold>. Network analysis of the principal differences in interactions between PDI genes and SLC34A2 gene in normal conditions and in tumor transformation, interaction of ERP29 and SLC34A2 genes in particular, opens new possibilities for development of therapeutic strategies, including monoclonal antibodies, for ovarian cancer treatment.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Рак яичников характеризуется высокой частотой развития рецидивов и химиорезистентности, поэтому поиск новых маркеров для прогнозирования заболевания и понимания фундаментальных процессов при онкогенной трансформации клеток яичника остается актуальной задачей. Мембранный фосфатный транспортер NaPi2b, кодируемый геном SLC34A2, высоко экспрессируется при данной патологии и служит мишенью для противоопухолевой терапии моноклональными антителами, направленными против эпитопа МХ35. Мы показали, что доступность эпитопа МХ35 зависит от конформации его большого внеклеточного домена, обусловленной дисульфидными связями (S-S-связи) между цистеинами в положениях 303, 322, 328 и 350. Известно, что белки семейства дисульфид-изомераз (protein disulfide isomerase, PDI) регулируют образование и перестройку S-S-связей.</p> <p><bold>Цель исследования</bold> – сетевой анализ взаимодействий SLC34A2 и генов семейства PDI, а также их продуктов в образцах нормальной и опухолевой тканей яичников для выявления ключевых регуляторов посттрансляционной модификации NaPi2b в опухолевых клетках.</p> <p><bold>Материалы и методы</bold>. Из баз данных Gene Ontology, String, KEGG, Reactome, WikiPathways, InterPro и Pfam получены сведения о взаимодействиях продуктов отобранных генов. На основе информации о коэкспрессии и белок-белковых взаимодействиях построены и проанализированы сети взаимодействий для 16 генов семейства PDI и гена SLC34A2 и их продуктов.</p> <p><bold>Результаты</bold>. В ходе топологического анализа выявлено отсутствие структурного сходства сетей (коэффициент кофенетической корреляции = 0,082), при этом в опухолях специфически ключевыми оказались гены CASQ1, CASQ2, ERP29, PDIA5, TMX4 и SLC34A2. Важнейшим результатом является объединение генов ERP29 и SLC34A2 в общий функциональный модуль с обратной коэкспрессией (коэффициент корреляции Спирмена = –0,42; p &lt;0,05) исключительно в сети взаимодействий в опухолевых клетках. Это указывает на потенциальную роль белка ERP29 в патологической перестройке дисульфидных связей внеклеточного домена NaPi2b и обеспечении доступности опухолеассоциированного эпитопа MX35 в трансформированных клетках.</p> <p><bold>Заключение</bold>. Сетевой анализ выявленных принципиальных различий во взаимодействиях генов PDI и гена SLC34A2 в норме и при опухолевой трансформации, в частности взаимодействие генов ERP29 и SLC34A2, открывает новые возможности для разработки терапевтических стратегий, в том числе для терапии моноклональными антителами рака яичников.</p></trans-abstract><kwd-group xml:lang="en"><kwd>NaPi2b</kwd><kwd>SLC34A2</kwd><kwd>protein disulfide isomerase</kwd><kwd>PDI</kwd><kwd>ovarian cancer</kwd><kwd>gene expression</kwd><kwd>protein-protein interaction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>NaPi2b</kwd><kwd>SLC34A2</kwd><kwd>дисульфид-изомеразы</kwd><kwd>PDI</kwd><kwd>рак яичника</kwd><kwd>экспрессия гена</kwd><kwd>белок-белковое взаимодействие</kwd></kwd-group><funding-group><funding-statement xml:lang="en">Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030)»</funding-statement><funding-statement xml:lang="ru">Программа стратегического академического лидерства Казанского (Приволжского) федерального университета (ПРИОРИТЕТ-2030).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI: 10.3322/caac.21763</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gaitskell K., Hermon C., Barnes I. et al. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiol 2022;76:102074. DOI: 10.1016/j.canep.2021.102074</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Salas Bolívar P., Gonzalez-Benitez C., Carbonell López M. et al. Prognostic factors after the first recurrence of ovarian cancer. J Clin Med 2025;14(2):470. DOI: 10.3390/jcm14020470</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gutic B., Bozanovic T., Mandic A. et al. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre. Clinics (Sao Paulo) 2023;78:100204. DOI: 10.1016/j.clinsp.2023.100204</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cheng X., Li P., Jiang R. et al. ADC: a deadly killer of platinum resistant ovarian cancer. J Ovarian Res 2024;17(1):196. DOI: 10.1186/s13048-024-01407-2</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Киямова Р.Г., Власенкова Р.А., Булатова Л.Ф. Натрий-зависимый фосфатный транспортер NaPi2b как мишень для таргетной терапии: особенности структуры, функции и экспрессии. Успехи молекулярной онкологии 2024;11(2):74–84. DOI: 10.17650/2313-805X-2024-11-2-74-84 Kiyamova R.G., Vlasenkova R.A., Bulatova L.F. Sodium-dependent phosphate transporter NaPi2b as a candidate for targeted therapy: features of structure, function, and expression. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2024;11(2):74–84. (In Russ.). DOI: 10.17650/2313-805X-2024-11-2-74-84</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Banerjee S., Drapkin R., Richardson D.L., Birrer M. Targeting NaPi2b in ovarian cancer. Cancer Treat Rev 2023;112:102489. DOI: 10.1016/j.ctrv.2022.102489</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bulatova L., Savenkova D., Nurgalieva A. et al. Toward a topology-based therapeutic design of membrane proteins: validation of NaPi2b topology in live ovarian cancer cells. Front Mol Biosci 2022;9:895911. DOI: 10.3389/fmolb.2022.895911</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Moore K.N., O’Malley D.M., Vergote I. et al. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2020;158(3):631–9. DOI: 10.1016/j.ygyno.2020.05.043</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schmitt S., Mai I., Machui P. et al. Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans. Cancer Res 2024;84(7_Suppl):2622. DOI: 10.1158/1538-7445.AM2024-2622</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Xiao L., Lian W., Liu Q. et al. Abstract 1894: preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors. Cancer Res 2024;84(6_Suppl):1894. DOI: 10.1158/1538-7445.AM2024-1894</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Huang W., Liu Z., Li Y. et al. Abstract 5907: pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b. Cancer Res 2024;84(6_Suppl):5907. DOI: 10.1158/1538-7445.AM2024-5907</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Horsley E., Jabeen A., Veillard N. et al. Abstract 5085: preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b. Cancer Res 2024;84(6_Suppl):5085. DOI: 10.1158/1538-7445.AM2024-5085</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Коротаева А.В., Булатова Л.Ф., Власенкова Р.А. и др. Распознавание Na-зависимого фосфатного транспортера NAPI2B моноклональными антителами в клетках бактерий и эукариот. Биотехнология 2022;38(5):66–72. DOI: 10.1134/S0234575522050078 Korotaeva A.V., Bulatova L.F., Vlasenkova R.A. et al. Recognition of the Na-dependent phosphate transporter NAPI2B by monoclonal antibodies in bacterial and eukaryotic cells. Biotekhnologiya = Biotechnology 2022;38(5):66–72. (In Russ.). DOI: 10.1134/S0234575522050078</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bulatova L.F., Skripova V.S., Sagdeeva A.R. et al. T330M substitution in the sodium-dependent phosphate transporter NaPi2b abolishes the efficacy of monoclonal antibodies against MX35 epitope. Antibodies 2025;14(2):30. DOI: 10.3390/antib14020030</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Xu S., Butkevich A.N., Yamada R. et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA 2012;109(40):16348–53. DOI: 10.1073/pnas.1205226109</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Feng S., Xu Y., Dai Z. et al. Integrative analysis from multicenter studies identifies a WGCNA-derived cancer-associated fibroblast signature for ovarian cancer. Front Immunol 2022;13:951582. DOI: 10.3389/fimmu.2022.951582</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Torrente A., Lukk M., Xue V. et al. Identification of cancer related genes using a comprehensive map of human gene expression. PLoS One 2016;11(6):e0157484. DOI: 10.1371/journal.pone.0157484</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Athar A., Füllgrabe A., George N. et al. ArrayExpress update – from bulk to single-cell expression data. Nucleic Acids Res 2019;47(D1):711–5. DOI: 10.1093/nar/gky964</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Bose A., Kasle G., Jana R. et al. Regulatory role of endoplasmic reticulum resident chaperone protein ERp29 in anti-murine β-coronavirus host cell response. J Biol Chem 2023;299(2):102836. DOI: 10.1016/j.jbc.2022.102836</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>McLaughlin T., Falkowski M., Wang J.J., Zhang S.X. Molecular chaperone ERp29: a potential target for cellular protection in retinal and neurodegenerative diseases. Adv Exp Med Biol 2018;1074:421–7. DOI: 10.1007/978-3-319-75402-4_52</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Carron J., Coser L., Lima C.S.P. et al. The impact of ERP29 on the progression of pharyngeal squamous cell carcinoma. Sci Rep 2024;14:25681. DOI: 10.1038/s41598-024-76210-6</mixed-citation></ref></ref-list></back></article>
